Search Results - "Kiran, Merve M."

Robust diagnosis of Ewing sarcoma by immunohistochemical detection of super-enhancer-driven EWSR1-ETS targets by Baldauf, Michaela C, Orth, Martin F, Dallmayer, Marlene, Marchetto, Aruna, Gerke, Julia S, Rubio, Rebeca Alba, Kiran, Merve M, Musa, Julian, Knott, Maximilian M L, Ohmura, Shunya, Li, Jing, Akpolat, Nusret, Akatli, Ayse N, Özen, Özlem, Dirksen, Uta, Hartmann, Wolfgang, de Alava, Enrique, Baumhoer, Daniel, Sannino, Giuseppina, Kirchner, Thomas, Grünewald, Thomas G P

“…Ewing sarcoma is an undifferentiated small-round-cell sarcoma. Although molecular detection of pathognomonic fusions such as enables definitive diagnosis,…”
Get full text

Systematic identification of cancer-specific MHC-binding peptides with RAVEN by Baldauf, Michaela C., Gerke, Julia S., Kirschner, Andreas, Blaeschke, Franziska, Effenberger, Manuel, Schober, Kilian, Rubio, Rebeca Alba, Kanaseki, Takayuki, Kiran, Merve M., Dallmayer, Marlene, Musa, Julian, Akpolat, Nurset, Akatli, Ayse N., Rosman, Fernando C., Özen, Özlem, Sugita, Shintaro, Hasegawa, Tadashi, Sugimura, Haruhiko, Baumhoer, Daniel, Knott, Maximilian M. L., Sannino, Giuseppina, Marchetto, Aruna, Li, Jing, Busch, Dirk H., Feuchtinger, Tobias, Ohmura, Shunya, Orth, Martin F., Thiel, Uwe, Kirchner, Thomas, Grünewald, Thomas G. P.

“…Immunotherapy can revolutionize anti-cancer therapy if specific targets are available. Immunogenic peptides encoded by cancer-specific genes (CSGs) may enable…”
Get full text

A rare lung tumor: Primary pulmonary synovial sarcoma by Sahin, Mehmet F, Beyoglu, Muhammet A, Kıran, Merve M, Yekeler, Erdal

“…Synovial sarcoma is one of the rare soft tissue sarcomas occurring in the periarticular region originating from synovia. Synovial sarcomas occur less…”
Get full text

Status of PD-1 and PD-L1 expression in invasive urothelial carcinoma of the bladder with mismatch repair protein deficiency by Sungu, Nuran, Kıran, Merve M.

“…It has been reported that mismatch repair deficient (d-MMR) tumors show sensitivity to immune checkpoint inhibitors. We aimed to evaluate the correlation of…”
Get full text

Gene expression and immunohistochemical analyses identify SOX2 as major risk factor for overall survival and relapse in Ewing sarcoma patients by Sannino, Giuseppina, Marchetto, Aruna, Ranft, Andreas, Jabar, Susanne, Zacherl, Constanze, Alba-Rubio, Rebeca, Stein, Stefanie, Wehweck, Fabienne S., Kiran, Merve M., Hölting, Tilman L.B., Musa, Julian, Romero-Pérez, Laura, Cidre-Aranaz, Florencia, Knott, Maximilian M.L., Li, Jing, Jürgens, Heribert, Sastre, Ana, Alonso, Javier, Da Silveira, Willian, Hardiman, Gary, Gerke, Julia S., Orth, Martin F., Hartmann, Wolfgang, Kirchner, Thomas, Ohmura, Shunya, Dirksen, Uta, Grünewald, Thomas G.P.

“…Up to 30–40% of Ewing sarcoma (EwS) patients with non-metastatic disease develop local or metastatic relapse within a time span of 2–10 years. This is in part…”
Get full text

Gene expression and immunohistochemical analyses identify SOX2 as major risk factor for overall survival and relapse in Ewing sarcoma patientsResearch in context by Giuseppina Sannino, Aruna Marchetto, Andreas Ranft, Susanne Jabar, Constanze Zacherl, Rebeca Alba-Rubio, Stefanie Stein, Fabienne S. Wehweck, Merve M. Kiran, Tilman L.B. Hölting, Julian Musa, Laura Romero-Pérez, Florencia Cidre-Aranaz, Maximilian M.L. Knott, Jing Li, Heribert Jürgens, Ana Sastre, Javier Alonso, Willian Da Silveira, Gary Hardiman, Julia S. Gerke, Martin F. Orth, Wolfgang Hartmann, Thomas Kirchner, Shunya Ohmura, Uta Dirksen, Thomas G.P. Grünewald

“…Background: Up to 30–40% of Ewing sarcoma (EwS) patients with non-metastatic disease develop local or metastatic relapse within a time span of 2–10 years. This…”
Get full text